glp 1 agonist meaning Frontiers Glucagon-like peptide 1 (GLP-1) -

The first half of 2025 has confirmed a seismic shift in the pharmaceutical landscape: GLP-1 receptor agonists a class of new drug therapies for diabetes and obesity now dominate global sales charts

Gently swirl the vial with a circular wrist motion

Although no current evidence suggests that GLP-1RAs induce -catenin mutations or APC deficiencies, it is hypothesized that prolonged use of GLP-1RAs may foster the proliferative progression of colorectal cancer cells and pancreatic -cells, based on their mechanisms of action [99]

doi: 10.1681/ASN.2021020167

Moreover, a retrospective real-world study shows that both GLP1-RA and SGLT-2 inhibitors reduce the 10-year risk for cardiovascular disease in patients with T2D in primary cardiovascular prevention [17], although SGLT-2 inhibitors seem to have a greater cardioprotective benefit compared to GLP-1RA when used for secondary prevention among adults with T2D [18]